Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab with PTCy for GVHD Prophylaxis in Reduced-Intensity Allogeneic HCT
NCT06996119Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Jun 2026
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emapalumab in graft-versus-host disease (GVHD), sponsored by City of Hope. Primary endpoints: Incidence of grade 3 or higher adverse events, Incidence of severe infusion reaction and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
emapalumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06996119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06996119.